Characteristics of Prostate Cancers Detected at Prostate Specific Antigen Levels Less Than 2.5 ng/ml

Journal of Urology

Volumn 181, Issue 6, 2009, Pages 2515-2519

  Meeks, Joshua J ^a   Loeb, Stacy ^b   Helfand, Brian T ^a   Kan, Donghui ^a   Smith, Norm D ^a   Catalona, William J ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

early detection of cancer; prostate specific antigen; prostatic neoplasms

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; ARTICLE; CANCER INVASION; CANCER SCREENING; CLINICAL FEATURE; DIGITAL RECTAL EXAMINATION; EARLY DIAGNOSIS; GLEASON SCORE; HEMOSPERMIA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PARAMETER; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE SPECIFIC ANTIGEN VELOCITY; PROTEIN BLOOD LEVEL; RADICAL RETROPUBIC PROSTATECTOMY; RISK ASSESSMENT; TRANSRECTAL ULTRASONOGRAPHY; TRANSURETHRAL RESECTION; TUMOR VOLUME;

HUMANS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS;

EID: 67349278591     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2009.01.102     Document Type: Article

References (12)

1. Lilja H., Ulmert D., and Vickers A.J. Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. Nat Rev Cancer 8 (2008) 268
2. Thompson I.M., Goodman P.J., Tangen C.M., Lucia M.S., Miller G.J., Ford L.G., et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 349 (2003) 215
3. Thompson I.M., Pauler D.K., Goodman P.J., Tangen C.M., Lucia M.S., Parnes H.L., et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med 350 (2004) 2239
4. Lucia M.S., Darke A.K., Goodman P.J., La Rosa F.G., Parnes H.L., Ford L.G., et al. Pathologic characteristics of cancers detected in The Prostate Cancer Prevention Trial: implications for prostate cancer detection and chemoprevention. Cancer Prev Res (Phila Pa) 1 (2008) 167
5. Humphrey P.A., and Vollmer R.T. Percentage carcinoma as a measure of prostatic tumor size in radical prostatectomy tissues. Mod Pathol 10 (1997) 326
6. Stamey T.A., Freiha F.S., McNeal J.E., Redwine E.A., Whittemore A.S., and Schmid H.P. Localized prostate cancer. Relationship of tumor volume to clinical significance for treatment of prostate cancer. Cancer 71 (1993) 933
7. Bastian P.J., Mangold L.A., Epstein J.I., and Partin A.W. Characteristics of insignificant clinical T1c prostate tumors. A contemporary analysis. Cancer 101 (2004) 2001
8. Lujan M., Paez A., Miravalles E., Fernandez I., Llanes L., and Berenguer A. Prostate cancer detection is also relevant in low prostate specific antigen ranges. Eur Urol 45 (2004) 155
9. Stephenson A.J., Jones J.S., Hernandez A.V., Ciezki J.P., Gong M.C., and Klein E.A. Analysis of T1c prostate cancers treated at very low prostate-specific antigen levels. Eur Urol (2008) Epub ahead of print
10. Schroder F.H., Roobol-Bouts M., Vis A.N., van der Kwast T., and Kranse R. Prostate-specific antigen-based early detection of prostate cancer-validation of screening without rectal examination. Urology 57 (2001) 83
11. Okotie O.T., Roehl K.A., Han M., Loeb S., Gashti S.N., and Catalona W.J. Characteristics of prostate cancer detected by digital rectal examination only. Urology 70 (2007) 1117
12. Kobayashi T., Mitsumori K., Kawahara T., Nishizawa K., Ogura K., and Ide Y. Prostate cancer detection among men with prostate specific antigen levels of 2.5 to 4.0 ng/ml in a Japanese urological referral population. J Urol 175 (2006) 1281